Clinical Scorecard: Prophylactic Strategies for Venous Thromboembolism in Total Shoulder Arthroplasty: Analysis of Matched Cohorts
At a Glance
Category
Detail
Condition
Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) post-total shoulder arthroplasty (TSA)
Key Mechanisms
Multifactorial risk influenced by patient factors (age, hypoalbuminemia, ethnicity, comorbidities) and procedure specifics; prophylaxis includes chemical agents (antiplatelets and anticoagulants) and mechanical methods
Target Population
Patients undergoing total shoulder arthroplasty, excluding those with recent anticoagulation or prior VTE within 5 years
Care Setting
Orthopedic surgical care, perioperative and postoperative management
Key Highlights
VTE incidence after TSA ranges from 0.2% to 16%, with larger studies reporting 0.24% to 0.68%.
No consensus exists on routine chemical prophylaxis for TSA; AAOS recommends individualized risk assessment.
Study compares outcomes of TSA patients with and without chemical VTE prophylaxis using a large matched cohort.
Guideline-Based Recommendations
Diagnosis
Use ICD-10-CM and CPT codes to identify VTE events post-TSA.
Assess patient risk factors including age, obesity, comorbidities, and surgery duration.
Management
Individualize VTE prophylaxis decisions based on patient risk assessment.
Chemical prophylaxis agents include aspirin, enoxaparin, rivaroxaban, apixaban, dabigatran, fondaparinux, warfarin, and argatroban.
Mechanical prophylaxis (e.g., compression devices) may be used but data not captured in this study.
Monitoring & Follow-up
Monitor for surgical complications (prosthetic joint infection, wound breakdown, hematoma).
Monitor for medical complications including bleeding events (head, GI, respiratory), ischemic stroke, myocardial infarction, and death.
Laboratory monitoring of hemoglobin and hematocrit postoperatively.
Risks
Potential bleeding complications associated with chemical prophylaxis.
No significant reduction in VTE incidence observed with chemoprophylaxis in some studies.
Risk factors such as older age, hypoalbuminemia, and fracture-related surgery increase VTE risk.
Patient & Prescribing Data
Patients undergoing total shoulder arthroplasty without prior recent anticoagulation or VTE history
Use of various chemical prophylactic agents is increasing, but comparative effectiveness and safety in TSA remain unclear; aspirin and direct factor Xa inhibitors are commonly used.
Clinical Best Practices
Perform individualized VTE risk assessment prior to TSA to guide prophylaxis decisions.
Consider patient-specific factors such as age, comorbidities, and surgical indication when choosing prophylaxis.
Recognize that routine chemical prophylaxis is not universally recommended for TSA due to low baseline VTE risk.
Monitor patients closely for bleeding and thrombotic complications postoperatively.
Use propensity matching and large database analyses to inform evidence-based prophylaxis strategies.
